The main risk is sequencing, not demand. Rocket Lab can likely sell more launch and spacecraft work than it can cleanly deliver over the next two years because
Neutron qualification, supplier bottlenecks, and acquisition integration all sit on the critical path. With the stock already extremely expensive on current revenue, even good execution can disappoint if
cash burn, program margins, or launch timing lag.